🟢 Aquestive Therapeutics is trading 11.11% up in pre-market after FDA accepts Anaphylm NDA resubmission as complete

Aquestive Therapeutics is trading at $4.20 (+11.11%) in pre-market after the FDA accepted the Anaphylm NDA resubmission as complete.

• The company announced the acceptance on October 15; the FDA set March 16, 2027, as the review goal date.
• The filing received a Class 2 review classification.
• Price context shows a rebound after several declining sessions; no pre-market volume data was provided.